MarketBeat
27 Oct 2026, 03:02 UTC · 2h ago
Impact · against what's priced in
Oruka's Phase IIb results for ORKA-001 are positive and supportive of a transition to Phase III in H1 2027. The report provides new catalysts including expected durability data in December and early 2027 readouts for ORKA-002.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish · 4 new · 1 priced in
ORKA-001 achieved complete skin clearance (PASI 100) in 61% of participants using the 600-milligram regimen at week 16 in the Phase IIb EVERLAST-B study.
New"Today, we're very pleased to share"
So whatThese results support the transition to Phase III, which is targeted for initiation in H1 2027.
More positive than 99% of claims this week
Continue reading
5 related stories
ORKA-001 achieved a 61% PASI 100 rate in the high-dose group of the EVERLAST-B study, replicating previous results and supporting a Phase III start in H1 2027. Additionally, the company established a clear catalyst timeline with week 52 data for ORKA-001 in December and Phase II results for ORKA-002 in Q1 2027.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Oruka plans to report week 52 durability data from the EVERLAST-A trial in December.
New"Today, we're very pleased to share"
More positive than 93% of claims this week
The company maintains a cash balance exceeding $1 billion as of the end of Q2.
Priced inrefers to end of second quarter
So whatThe balance provides sufficient runway through the Biologics License Application (BLA) filing, reducing near-term dilution risk.
More positive than 78% of claims this week
Initial Phase II results for ORKA-002 in psoriasis are expected in the first quarter of 2027.
New"Today, we're very pleased to share"
So whatThis adds a secondary clinical catalyst to the 2027 horizon alongside the ORKA-001 Phase III start.
More positive than 64% of claims this week
ORKA-004, an extended-half-life TL1A antibody, is expected to enter Phase I around year-end.
New"Today, we're very pleased to share"
So whatCombination studies for this asset are scheduled to follow in 2027.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 97% of ticker scores this week
The company reported positive Phase IIb results for ORKA-001 showing high rates of skin clearance and a strong safety profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
14h ago
—
ORKA hasn't traded since this ran. Last close $90.33 (Oct 26); the reaction starts at the next open.
ORKA chart →
